ResMed stock (US7611521078): sleep apnea specialist in focus after latest earnings

ResMed has reported fresh quarterly figures and updated investors on demand for its sleep apnea devices and masks. What drives the business, and what should US investors know about the company’s core markets and revenue model?

ResMed reported results for its fiscal third quarter 2025 on April 24, 2025, highlighting continued growth in demand for its sleep and respiratory care devices, according to a press release published the same day on the company’s website and by the Australian Securities Exchange ResMed investor update as of 04/24/2025. The company pointed to solid sales of masks and accessories as well as cloud-connected ventilators, while also commenting on margin trends and ongoing investments in digital health platforms, as reported by Reuters as of 04/24/2025.

As of: 05/21/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: ResMed Inc.
• Sector/industry: Medical technology, sleep and respiratory care
• Headquarters/country: San Diego, United States
• Core markets: North America, Europe, Asia-Pacific
• Key revenue drivers: Sleep apnea devices, masks and accessories, cloud-connected ventilators, software-as-a-service for out-of-hospital care
• Home exchange/listing venue: NYSE (ticker: RMD) and ASX (ticker: RMD)
• Trading currency: Primarily USD on NYSE

ResMed Inc.: core business model

ResMed focuses on medical devices and digital health solutions that diagnose, treat and manage sleep apnea, chronic obstructive pulmonary disease (COPD) and related respiratory conditions. The company’s core franchise centers on positive airway pressure (PAP) devices and masks that help keep airways open during sleep. These products are typically prescribed for obstructive sleep apnea and are used on a long-term basis, generating recurring demand for masks and accessories as components are replaced over time.

A second pillar of the business is ventilation systems for chronic respiratory disease patients, including life support ventilators and non-invasive devices used at home or in healthcare facilities. Many of these systems are cloud-connected, allowing clinicians to remotely monitor adherence and adjust therapy settings. ResMed has invested heavily in its cloud platform, enabling automatic data uploads from devices, which can improve treatment outcomes and support reimbursement requirements in key markets such as the United States.

Beyond hardware, ResMed has built a portfolio of software-as-a-service solutions aimed at out-of-hospital care providers. These platforms, which include tools for managing home medical equipment providers, sleep labs and long-term care facilities, are designed to streamline workflows, automate billing and support patient engagement. The digital segment adds a subscription-like element to the revenue mix and ties customers into ResMed’s ecosystem, as noted in company presentations released on February 8, 2024, alongside fiscal second quarter 2024 results ResMed investor materials as of 02/08/2024.

The business model is therefore built on a combination of durable medical equipment sales, high-margin consumables and recurring software revenue. In major markets such as the United States, payers and insurers reimburse sleep apnea treatment when specific adherence thresholds are met, which aligns with ResMed’s focus on remote monitoring and data-driven care. This structure encourages ongoing patient use and supports long-term relationships with providers, which can be a competitive advantage in the sleep and respiratory care space.

Main revenue and product drivers for ResMed Inc.

ResMed’s largest revenue contributor is its Sleep and Respiratory Care segment, which includes PAP devices, masks and accessories sold through home medical equipment providers and healthcare systems. Masks and related accessories are particularly important for profitability, as they are replaced regularly due to wear and hygiene requirements. In the company’s fiscal year 2024 report, published on August 8, 2024, ResMed highlighted continued growth in mask and accessory sales, driven by both an expanding installed base of devices and increasing awareness of sleep apnea in key markets ResMed annual report as of 08/08/2024.

Device volumes are influenced by diagnostic rates for sleep apnea and the capacity of sleep labs and home testing providers. In the United States, rising use of home sleep testing and broader screening of patients with risk factors, such as obesity and cardiovascular disease, have supported demand for therapy devices. ResMed has emphasized its role in scaling home-based diagnostics and therapy, noting in earnings presentations that home sleep tests can accelerate time to treatment and reduce barriers compared with traditional in-lab studies, as summarized in materials accompanying fiscal third quarter 2024 results on April 25, 2024 ResMed news update as of 04/25/2024.

The company’s cloud-based AirView and myAir platforms are another key driver. These systems collect data from connected devices, allowing physicians and providers to track adherence, troubleshoot issues remotely and adjust therapy without an in-person visit. For patients, smartphone apps can provide feedback on nightly sleep quality and coaching tips, potentially improving compliance. Because adherence data are critical for insurer reimbursement in the US market, the ability to document usage can support continued coverage, making digital capabilities an integral part of the value proposition.

ResMed’s software-as-a-service business, often reported as the Software-as-a-Service or SaaS segment, contributes a growing share of revenue. Solutions acquired over recent years, including platforms for managing electronic health records and care coordination in post-acute and long-term care, generate subscription revenue and recurring fees. In the fiscal year 2023 annual report published on August 10, 2023, ResMed noted double-digit revenue growth in its software segment, citing increased adoption among home health and hospice providers seeking to digitize workflows and support regulatory reporting ResMed annual report as of 08/10/2023.

Pricing and mix also play a role in ResMed’s revenue trajectory. The company has reported that premium devices with advanced comfort features and connectivity can command higher prices, while reimbursement frameworks in markets such as the US and Germany set reference levels for standard equipment. Supply chain dynamics and component costs influence gross margins; ResMed has described efforts to manage input costs and logistics expenses, particularly in the wake of global disruptions, in commentary accompanying quarterly updates throughout 2023 and 2024. The balance between device sales, consumables and software, along with cost control, therefore shapes the company’s earnings profile over time.

Conclusion

ResMed occupies a central position in the global market for sleep apnea and respiratory care, combining hardware, consumables and digital platforms into a cohesive offering. Recent earnings updates have underscored the importance of mask and accessory sales, cloud connectivity and software-as-a-service solutions in driving growth, alongside careful management of costs and margins. For US investors, the dual listing on the NYSE and ASX, exposure to reimbursement-driven demand in the American healthcare system and participation in the broader trend toward home-based and data-enabled care make the stock a notable name within the medical technology universe. At the same time, factors such as competition, regulatory changes and shifts in diagnostic patterns remain important variables for the company’s long-term trajectory.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.